Dr. Jamal Misleh, MD
Claim this profileMedical Oncology Hematology Consultants, PA
Expert in Breast Cancer
Studies Cancer
28 reported clinical trials
48 drugs studied
About Jamal Misleh, MD
Education:
- Obtained MD from the University of Miami School of Medicine in 2003.
Experience:
- Completed an Internal Medicine Internship (2003-2004) and Residency (2004-2006) at the Hospital of the University of Pennsylvania.
- Undertook a Fellowship in Hematology/Medical Oncology at the University of Maryland Medical Center (2006-2009).
- Board Certified in Hematology and Medical Oncology by the American Board of Internal Medicine since 2009.
- Affiliated with Medical Oncology Hematology Consultants, PA, and serves as the Director of US Oncology Network Clinical Trials.
Area of expertise
1Breast Cancer
Global LeaderStage IV
Stage III
HER2
2Cancer
Stage IV
EZH2 positive
CNG positive
Affiliated Hospitals
Clinical Trials Jamal Misleh, MD is currently running
ARX788
for HER2-Positive Breast Cancer
This trial tests ARX788, a new IV medicine, for patients with HER2-positive metastatic breast cancer who did not respond well to T-DXd. The medicine targets a specific protein on cancer cells to help stop their growth.
Recruiting1 award Phase 28 criteria
Fruquintinib
for Colorectal Cancer
High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib for refractory mCRC. Other aims are to learn how safe fruquintinib is and how well it is tolerated by participants. Participants will receive fruquintinib in 4-week treatment cycles until their condition worsens, they do no longer tolerate the treatment or stop the treatment for other reasons. After the last treatment, participants will be checked upon every 3 months until study completion.
Recruiting3 awards Phase 46 criteria
More about Jamal Misleh, MD
Clinical Trial Related2 years of experience running clinical trials · Led 28 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Jamal Misleh, MD has experience with
- Pembrolizumab
- Abemaciclib
- Placebo
- Rituximab
- LOXO-305
- Botensilimab
Breakdown of trials Jamal Misleh, MD has run
Breast Cancer
Cancer
Colorectal Cancer
Uterine Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jamal Misleh, MD specialize in?
Jamal Misleh, MD focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are Stage III.
Is Jamal Misleh, MD currently recruiting for clinical trials?
Yes, Jamal Misleh, MD is currently recruiting for 9 clinical trials in Newark Delaware. If you're interested in participating, you should apply.
Are there any treatments that Jamal Misleh, MD has studied deeply?
Yes, Jamal Misleh, MD has studied treatments such as Pembrolizumab, Abemaciclib, Placebo.
What is the best way to schedule an appointment with Jamal Misleh, MD?
Apply for one of the trials that Jamal Misleh, MD is conducting.
What is the office address of Jamal Misleh, MD?
The office of Jamal Misleh, MD is located at: Medical Oncology Hematology Consultants, PA, Newark, Delaware 19713 United States. This is the address for their practice at the Medical Oncology Hematology Consultants, PA.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.